Rtw Biotech Regulatory News (RTW)

1 September 2021

RTW Venture Fund Limited

(the "Company")

TOTAL VOTING RIGHTS

In accordance with DTR 5.6.1R as at 31 August 2021 the Company had 209,799,033 Ordinary Shares in issue, each with equal voting rights and no shares held in Treasury.

The total voting rights figure can be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information, please contact:

RTW Investments, LP +1 (646) 343 9280

Stephanie Sirota, Chief Business Officer

Alexandra Taracanova, PhD, Director of Investor Relations

Elysium Fund Management Limited +44 (0) 14 8181 0100

Joanna Duquemin Nicolle, Chief Executive Officer

Sadie Morrison, Managing Director

Morgan Stanley Fund Services USA LLC +1 (914) 225-8885

J.P. Morgan Cazenove +44 (0) 20 7742 4000

William Simmonds

James Bouverat (Sales)

Barclays +44 (0) 20 7623 2323

Tom Swerling

Andrew Tusa

About RTW Venture Fund Limited:

RTW Venture Fund Limited (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.

RTW Venture Fund Limited is managed by RTW Investments, LP, a leading US healthcare investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the RTW website at www.rtwfunds.com for more information.